Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CCKBR | P32239 | 5/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | CCKAR | P32238 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.34 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7547991 | 1.00 | ALDH1A1 (0.39) | ALDH1A1MEN1KMT2ACCKBRGFER | |
| SCHEMBL7544795 | 0.86 | MEN1 (0.38) | ALDH1A1MEN1KMT2ACCKBRGFER | |
| SCHEMBL7601420 | 0.86 | MEN1 (0.38) | ALDH1A1MEN1KMT2ACCKBRGFER | |
| SCHEMBL7552264 | 0.84 | MEN1 (0.41) | ALDH1A1MEN1KMT2ACCKBRGFER | |
| SCHEMBL7552256 | 0.84 | MEN1 (0.41) | ALDH1A1MEN1KMT2ACCKBRGFER | |
| SCHEMBL7544295 | 0.80 | CCKBR (0.43) | ALDH1A1MEN1KMT2ACCKBRGFER | |
| SCHEMBL7544285 | 0.80 | CCKBR (0.43) | ALDH1A1MEN1KMT2ACCKBRGFER | |
| SCHEMBL7546890 | 0.78 | CHRM1 (0.40) | ALDH1A1MEN1KMT2ACCKBRGFER | |
| SCHEMBL7546878 | 0.78 | CHRM1 (0.40) | ALDH1A1MEN1KMT2ACCKBRGFER | |
| SCHEMBL7546466 | 0.76 | CCKBR (0.52) | ALDH1A1MEN1KMT2ACCKBRGFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020183313-A1 | 1,4-benzodiazepinones and their uses as CCK antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-12-05 | — | — | US | disclosed |
| US-20020002163-A1 | 1,4-benzodiazepinones and their uses as CCK antagonists | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-01-03 | — | — | US | disclosed |
| US-6291452-B1 | CHOLECYSTOKININ ANTAGONISTS. | FUJISAWA PHARMACETICAL CO., LTD. (JP) | 2001-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020002163-A1 | 1,4-benzodiazepinones and their uses as CCK antagonists | CCKAR, CCKBR, GABRA4 | ALDH1A1 1169/4885MEN1 2261/4885KMT2A 1298/4885 |
| US-20020183313-A1 | 1,4-benzodiazepinones and their uses as CCK antagonists | CCKAR, CCKBR, GABRA4 | ALDH1A1 1169/4885MEN1 2261/4885KMT2A 1298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.